267 related articles for article (PubMed ID: 35267028)
21. Gene addition for beta thalassemia.
Kwiatkowski JL
Ann N Y Acad Sci; 2023 Dec; 1530(1):105-109. PubMed ID: 37828865
[TBL] [Abstract][Full Text] [Related]
22. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
23. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia.
Cavazzana-Calvo M; Payen E; Negre O; Wang G; Hehir K; Fusil F; Down J; Denaro M; Brady T; Westerman K; Cavallesco R; Gillet-Legrand B; Caccavelli L; Sgarra R; Maouche-Chrétien L; Bernaudin F; Girot R; Dorazio R; Mulder GJ; Polack A; Bank A; Soulier J; Larghero J; Kabbara N; Dalle B; Gourmel B; Socie G; Chrétien S; Cartier N; Aubourg P; Fischer A; Cornetta K; Galacteros F; Beuzard Y; Gluckman E; Bushman F; Hacein-Bey-Abina S; Leboulch P
Nature; 2010 Sep; 467(7313):318-22. PubMed ID: 20844535
[TBL] [Abstract][Full Text] [Related]
24. Recent Progress in Gene Therapy and Other Targeted Therapeutic Approaches for Beta Thalassemia.
Hamed EM; Meabed MH; Aly UF; Hussein RRS
Curr Drug Targets; 2019; 20(16):1603-1623. PubMed ID: 31362654
[TBL] [Abstract][Full Text] [Related]
25. Universal Gene Correction Approaches for β-hemoglobinopathies Using CRISPR-Cas9 and Adeno-Associated Virus Serotype 6 Donor Templates.
Lamsfus-Calle A; Daniel-Moreno A; Ureña-Bailén G; Rottenberger J; Raju J; Epting T; Marciano S; Heumos L; Baskaran P; S Antony J; Handgretinger R; Mezger M
CRISPR J; 2021 Apr; 4(2):207-222. PubMed ID: 33876951
[TBL] [Abstract][Full Text] [Related]
26. Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy.
Porter J
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):361-370. PubMed ID: 30504333
[TBL] [Abstract][Full Text] [Related]
27. Hematopoietic stem cell gene transfer for the treatment of hemoglobin disorders.
Persons DA
Hematology Am Soc Hematol Educ Program; 2009; ():690-7. PubMed ID: 20008255
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Effects of Hematopoietic Stem Cell Derived From Gene-Edited Mice on β654-Thalassemia.
Lu D; Gong X; Guo X; Chen Y; Zhu Y; Fang Y; Cai Q; Xu M; Yang H; Li D; Zeng Y; Zeng F
Stem Cells; 2024 Mar; 42(3):278-289. PubMed ID: 38134938
[TBL] [Abstract][Full Text] [Related]
29. [Research Progress on Gene Therapy for β-thalassemia---Review].
Hong WC; Fang JP; Xu LH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1676-1679. PubMed ID: 34627461
[TBL] [Abstract][Full Text] [Related]
30. Lentiviral globin gene therapy with reduced-intensity conditioning in adults with β-thalassemia: a phase 1 trial.
Boulad F; Maggio A; Wang X; Moi P; Acuto S; Kogel F; Takpradit C; Prockop S; Mansilla-Soto J; Cabriolu A; Odak A; Qu J; Thummar K; Du F; Shen L; Raso S; Barone R; Di Maggio R; Pitrolo L; Giambona A; Mingoia M; Everett JK; Hokama P; Roche AM; Cantu VA; Adhikari H; Reddy S; Bouhassira E; Mohandas N; Bushman FD; Rivière I; Sadelain M
Nat Med; 2022 Jan; 28(1):63-70. PubMed ID: 34980909
[TBL] [Abstract][Full Text] [Related]
31. [Advance of research on the role of BCL11A in the occurrence and treatment of β-Thalassemia].
Lyu A; Chen M; Xu L; Huang H
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2024 Apr; 41(4):417-425. PubMed ID: 38565506
[TBL] [Abstract][Full Text] [Related]
32. Gene Therapy for beta-thalassemia.
Malik P; Arumugam PI
Hematology Am Soc Hematol Educ Program; 2005; ():45-50. PubMed ID: 16304358
[TBL] [Abstract][Full Text] [Related]
33. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer.
Rivella S; May C; Chadburn A; Rivière I; Sadelain M
Blood; 2003 Apr; 101(8):2932-9. PubMed ID: 12480689
[TBL] [Abstract][Full Text] [Related]
34. Gene Therapy for β-Hemoglobinopathies.
Cavazzana M; Antoniani C; Miccio A
Mol Ther; 2017 May; 25(5):1142-1154. PubMed ID: 28377044
[TBL] [Abstract][Full Text] [Related]
35. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
36. Genetic therapy for beta-thalassemia: from the bench to the bedside.
Arumugam P; Malik P
Hematology Am Soc Hematol Educ Program; 2010; 2010():445-50. PubMed ID: 21239833
[TBL] [Abstract][Full Text] [Related]
37. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
Langer AL; Esrick EB
Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
[TBL] [Abstract][Full Text] [Related]
38. Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β(A(T87Q))-Globin Gene.
Negre O; Eggimann AV; Beuzard Y; Ribeil JA; Bourget P; Borwornpinyo S; Hongeng S; Hacein-Bey S; Cavazzana M; Leboulch P; Payen E
Hum Gene Ther; 2016 Feb; 27(2):148-65. PubMed ID: 26886832
[TBL] [Abstract][Full Text] [Related]
39. Health state utilities associated with treatment for transfusion-dependent β-thalassemia.
Matza LS; Paramore LC; Stewart KD; Karn H; Jobanputra M; Dietz AC
Eur J Health Econ; 2020 Apr; 21(3):397-407. PubMed ID: 31828456
[TBL] [Abstract][Full Text] [Related]
40. Improved hematopoietic differentiation efficiency of gene-corrected beta-thalassemia induced pluripotent stem cells by CRISPR/Cas9 system.
Song B; Fan Y; He W; Zhu D; Niu X; Wang D; Ou Z; Luo M; Sun X
Stem Cells Dev; 2015 May; 24(9):1053-65. PubMed ID: 25517294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
